ABEO Stock Analysis: Abeona Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 360m USD | 12M Return: 13.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.24M
Qual. Beats: 0
Rev. Trend: 54.7%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Abeona Therapeutics Inc. (NASDAQ: ABEO) is a commercial-stage biopharmaceutical company headquartered in Cleveland, Ohio. Founded in 1974 and previously known as PlasmaTech Biopharmaceuticals, the company focuses on developing gene and cell therapies for life-threatening diseases in the United States.
Its lead product, ZEVASKYN, is an autologous, cell-based gene therapy for recessive dystrophic epidermolysis bullosa. Autologous therapies are manufactured using a patients own cells, which are genetically modified outside the body and reinfused, allowing for personalized treatment but requiring individualized production runs.
Abeonas pipeline includes ABO-503 for X-linked retinoschisis, ABO-504 for Stargardt disease, and ABO-505 for autosomal dominant optic atrophy. The company also develops AAV-based gene therapies through its AIM vector platform. Adeno-associated virus (AAV) vectors are a common gene-delivery tool in the biotech industry because they can target specific tissues while generally triggering a limited immune response.
- ZEVASKYN commercial launch drives first gene therapy revenue
- Ophthalmology pipeline ABO-503 and ABO-504 advances through clinical milestones
- Limited cash runway may force dilutive equity offering to fund operations
| Net Income: 66.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.43 > 0.02 and ΔFCF/TA 20.46 > 1.0 |
| NWC/Revenue: 1.04k% < 20% (prev 1.47k%; Δ -421.7% < -1%) |
| CFO/TA -0.39 > 3% & CFO -77.7m > Net Income 66.1m |
| Net Debt (-140.0m) to EBITDA (73.4m): -1.91 < 3 |
| Current Ratio: 5.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (56.6m) vs 12m ago 13.74% < -2% |
| Gross Margin: 51.93% > 18% (prev 16.77%; Δ 35.15% > 0.5%) |
| Asset Turnover: 9.76% > 50% (prev 4.81%; Δ 4.95% > 0%) |
| Interest Coverage Ratio: 19.54 > 6 (EBIT TTM 69.8m / Interest Expense TTM 3.57m) |
| A: 0.77 (Total Current Assets 183.0m - Total Current Liabilities 31.0m) / Total Assets 198.5m |
| B: -3.82 (Retained Earnings -759.1m / Total Assets 198.5m) |
| C: 0.47 (EBIT TTM 69.8m / Avg Total Assets 148.9m) |
| D: 2.71 (Book Value of Equity 144.9m / Total Liabilities 53.6m) |
| Altman-Z'' = -1.45 = CCC |
| DSRI: 1.36 (Receivables 6.71m/1.62m, Revenue 14.5m/4.78m) |
| GMI: 0.32 (GM 16.77% / 51.93%) |
| AQI: 7.26 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 3.04 (Revenue 14.5m / 4.78m) |
| TATA: 0.72 (NI 66.1m - CFO -77.7m) / TA 198.5m) |
| Beneish M = 1.92 (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 6.55 with a total of 1,658,907 shares traded. Over the past week, the price has changed by +15.72%, over one month by +21.75%, over three months by +36.17% and over the past year by +13.91%.
Current recommended Stop Loss: 6.20 (which is 5.3% or 1.3 ATR below the current price).
Abeona Therapeutics has received a consensus analysts rating of 4.83. Therefore, it is recommended to buy ABEO.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.7 | 200.9% |
P/E Trailing = 6.6421
P/E Forward = 526.3158
P/S = 24.7345
P/B = 2.5167
Revenue TTM = 14.5m USD
EBIT TTM = 69.8m USD
EBITDA TTM = 73.4m USD
Long Term Debt = 4.75m USD (from longTermDebt, last quarter)
Short Term Debt = 14.6m USD (from shortTermDebt, last quarter)
Debt = 28.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 5.09m
Net Debt = -140.0m USD (calculated: Debt 28.3m - CCE 168.3m)
Enterprise Value = 219.6m USD (359.6m + Debt 28.3m - CCE 168.3m)
Interest Coverage Ratio = 19.54 (Ebit TTM 69.8m / Interest Expense TTM 3.57m)
EV/FCF = -2.58x (Enterprise Value 219.6m / FCF TTM -85.2m)
FCF Yield = -38.81% (FCF TTM -85.2m / Enterprise Value 219.6m)
FCF Margin = -586.2% (FCF TTM -85.2m / Revenue TTM 14.5m)
Net Margin = 454.9% (Net Income TTM 66.1m / Revenue TTM 14.5m)
Gross Margin = 51.93% ((Revenue TTM 14.5m - Cost of Revenue TTM 6.99m) / Revenue TTM)
Gross Margin QoQ = 59.12% (prev 47.66%)
Tobins Q-Ratio = 1.11 (Enterprise Value 219.6m / Total Assets 198.5m)
Interest Expense / Debt = 12.64% (Interest Expense 3.57m / Debt 28.3m)
Taxrate = 0.15% (102k / 66.2m)
NOPAT = 69.7m (EBIT 69.8m * (1 - 0.15%))
Current Ratio = 5.89 (Total Current Assets 183.0m / Total Current Liabilities 31.0m)
Debt / Equity = 0.19 (Debt 28.3m / totalStockholderEquity, last quarter 144.9m)
Debt / EBITDA = -1.91 (Net Debt -140.0m / EBITDA 73.4m)
Debt / FCF = 1.64 (negative FCF - burning cash) (Net Debt -140.0m / FCF TTM -85.2m)
Total Stockholder Equity = 159.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 44.41% (Net Income 66.1m / Total Assets 198.5m)
RoE = 41.40% (Net Income TTM 66.1m / Total Stockholder Equity 159.7m)
RoCE = 42.44% (EBIT 69.8m / Capital Employed (Equity 159.7m + L.T.Debt 4.75m))
RoIC = 38.44% (NOPAT 69.7m / Invested Capital 181.3m)
WACC = 11.14% (E(359.6m)/V(387.9m) * Re(11.02%) + D(28.3m)/V(387.9m) * Rd(12.64%) * (1-Tc(0.00)))
Discount Rate = 11.02% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 64.44 | Cagr: 42.41%
[DCF] Fair Price = unknown (Cash Flow -85.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.21 | # QB: 0
Revenue Correlation: 54.66 | Revenue CAGR: 30.66% | SUE: 1.55 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.23 | Chg30d=+19.55% | Revisions=-50% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.11 | Chg30d=+31.25% | Revisions=-50% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.68 | Chg30d=+24.64% | Revisions=-50% | GrowthEPS=+44.7% | GrowthRev=+1025.6%
EPS next Year (2027-12-31): EPS=0.29 | Chg30d=+19.46% | Revisions=-50% | GrowthEPS=+141.9% | GrowthRev=+106.0%
[Analyst] Revisions Ratio: -80% (up=0, down=12)